Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

ClinicalTrials.gov ID: NCT05599191

Public ClinicalTrials.gov record NCT05599191. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 27, 2026, 3:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1)

Study identification

NCT ID
NCT05599191
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Enrollment
825 participants

Conditions and interventions

Interventions

  • BLU-5937 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 24, 2022
Primary completion
Dec 17, 2025
Completion
May 27, 2026
Last update posted
Jun 9, 2025

2022 – 2026

United States locations

U.S. sites
65
U.S. states
28
U.S. cities
60
Facility City State ZIP Site status
GSK Investigational Site Litchfield Park Arizona 85340
GSK Investigational Site Scottsdale Arizona 85248
GSK Investigational Site Encinitas California 92024
GSK Investigational Site Mission Viejo California 92691
GSK Investigational Site Paramount California 90723
GSK Investigational Site Roseville California 95661
GSK Investigational Site Aurora Colorado 80012
GSK Investigational Site Colorado Springs Colorado 80923
GSK Investigational Site Clearwater Florida 33756
GSK Investigational Site Gainesville Florida 32608
GSK Investigational Site Miami Florida 15801
GSK Investigational Site Miami Florida 33155
GSK Investigational Site Miami Florida 33173
GSK Investigational Site Miami Florida 33186
GSK Investigational Site Orlando Florida 32713
GSK Investigational Site Lawrenceville Georgia 30046
GSK Investigational Site Normal Illinois 61761
GSK Investigational Site Oak Lawn Illinois 60453
GSK Investigational Site Ames Iowa 50010
GSK Investigational Site Iowa City Iowa 52242
GSK Investigational Site Kansas City Kansas 66160
GSK Investigational Site Topeka Kansas 66606
GSK Investigational Site Wichita Kansas 67214
GSK Investigational Site Crowley Louisiana 70526
GSK Investigational Site Shreveport Louisiana 71115
GSK Investigational Site Annapolis Maryland 21404
GSK Investigational Site North Dartmouth Massachusetts 02747
GSK Investigational Site Ann Arbor Michigan 48109
GSK Investigational Site Ypsilanti Michigan 48197
GSK Investigational Site Columbia Missouri 65203
GSK Investigational Site St Louis Missouri 63110
GSK Investigational Site St Louis Missouri 63141
GSK Investigational Site Missoula Montana 59808
GSK Investigational Site Jersey City New Jersey 07304
GSK Investigational Site The Bronx New York 10461
GSK Investigational Site Charlotte North Carolina 28277
GSK Investigational Site Raleigh North Carolina 28401
GSK Investigational Site Rocky Mount North Carolina 27804
GSK Investigational Site Salisbury North Carolina 28144
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site Columbus Ohio 43215
GSK Investigational Site Dayton Ohio 45417
GSK Investigational Site Oklahoma City Oklahoma 73104
GSK Investigational Site Tulsa Oklahoma 74136
GSK Investigational Site Medford Oregon 97504
GSK Investigational Site Portland Oregon 97202
GSK Investigational Site Philadelphia Pennsylvania 19140
GSK Investigational Site Warwick Rhode Island 02886
GSK Investigational Site Charleston South Carolina 29406
GSK Investigational Site Little River South Carolina 29566
GSK Investigational Site Mt. Pleasant South Carolina 29464
GSK Investigational Site Rock Hill South Carolina 29732
GSK Investigational Site Bristol Tennessee 37620
GSK Investigational Site Knoxville Tennessee 37938
GSK Investigational Site Dallas Texas 75231-4307
GSK Investigational Site Houston Texas 77074
GSK Investigational Site Houston Texas 77401
GSK Investigational Site McKinney Texas 75069
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Waco Texas 76712
GSK Investigational Site Salt Lake City Utah 84132
GSK Investigational Site Norfolk Virginia 23507
GSK Investigational Site Williamsburg Virginia 23188
GSK Investigational Site Bellevue Washington 68123
GSK Investigational Site Bellingham Washington 98225

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 126 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05599191, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 9, 2025 · Synced Jun 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05599191 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →